Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can ketamine quickly quiet suicidal thoughts? new brain scan study aims to find out

NCT ID NCT06891300

Symptom relief Sponsor: The Royal's Institute of Mental Health Research Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether four intravenous ketamine infusions over two weeks can reduce suicidal thoughts in 36 adults with major depression. Participants will also have two MRI brain scans to see if changes in brain structure relate to symptom improvement. The goal is to both treat suicidal ideation and understand the biological mechanisms behind it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine hydrochloride
What this could lead to
If successful, this could point toward a fast-acting treatment for suicidal thoughts in depression and help explain how ketamine changes the brain.
What could go wrong
This is a small, early-phase study with only 36 participants, so results may not apply to everyone. Ketamine can cause side effects like dissociation or nausea, and the effect on suicidal thoughts may not last.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. English speaking 2. Ages 18-65 years old 3. Suicidal ideation severity score ≥3 on the Columbia Suicide Severity Rating Scale (C-SSRS) (Baseline/Screening version) at Screening Visit ("active suicidal ideation with any methods") 4. Diagnosis of Major Depressive Disorder (MDD) according to the Diagnostic and Statistical Manual for Mental Disorders 5th Edition (DSM-5) 5. Willing to maintain stable doses of concomitant medications throughout the study 6. Be under the care of a designated health care provider (i.e., family physician or psychiatrist) to follow their care after the completion of the study. Exclusion Criteria: 1. Participants not medically cleared to receive ketamine treatment due to presence of clinically relevant disease (e.g., uncontrolled hypertension, renal or hepatic impairment, significant coronary artery disease, diabetes mellitus, seizure disorder). 2. Known or suspected hypersensitivity or intolerance to ketamine 3. Body mass index (BMI) ≥35 4. History of a primary psychotic disorder (e.g., schizophrenia), or current or recent (\<2 years) acute episode of psychosis 5. Current and/or recent history (\<12 months) of substance use/dependence (except for caffeine or nicotine) or problematic current alcohol use or dependence as defined by DSM-5 criteria 6. Pregnant, breastfeeding or of childbearing potential and unwilling to use an approved method of contraception during the study 7. History of significant head injury including loss of consciousness \>5 minutes 8. Any MRI contraindications 9. Concurrent use of ketamine in any form 10. Concurrent active ECT or repetitive transcranial magnetic stimulation (rTMS) therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder Suicidal Ideation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depressive disorder (MDD) Suicidal ideation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal Ottawa Mental Health Centre

    RECRUITING

    Ottawa, Ontario, K1Z7K4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.